AngioDynamics (ANGO) to Host NanoKnife Investor Event

AngioDynamics, Inc. (“AngioDynamics”) is set to host the virtual NanoKnife Irreversible Electroporation (IRE) Prostate Investor Event on January 8, 2025. The company’s presentation slides, filed as Exhibit 99.1 with the Securities and Exchange Commission on the same date, provide insights into AngioDynamics’ anticipated future financial standing, operational outcomes, strategic directives, and growth pursuits.

The presentation slides, as per the Form 8-K disclosure under Item 7.01, contain forward-looking statements in compliance with the Private Securities Litigation Reform Act of 1995. These statements encompass AngioDynamics’ expectations related to financial performance, operational results, business plans, competitive positioning, and growth opportunities. However, it is noted that actual results may vary due to inherent risks and uncertainties.

Among the significant factors that may impact AngioDynamics’ performance are the scale of the ongoing global COVID-19 pandemic, product development capabilities, regulatory landscape, economic conditions, market trends, competitive dynamics, and potential challenges related to technology infringement. The company emphasizes that forward-looking statements are not foolproof indicators of future outcomes.

The NanoKnife System, highlighted in the presentation, stands as the sole FDA-cleared technology that employs electricity for targeted prostate tissue destruction. The technology boasts a robust intellectual property portfolio alongside noteworthy clinical outcomes supported by numerous studies. With a focus on strategic market entry and favorable regulatory approvals, AngioDynamics aims to foster novel growth avenues in the medical technology sphere.

Taking a proactive stance, AngioDynamics continuously assesses market conditions, adjusts its product portfolio, and reinforces its operational structure to enhance resilience and profitability. The company’s commitment to driving innovation and pursuing transformative strategies underscores its dedication to meeting evolving healthcare demands.

Investors and stakeholders are encouraged to review the presentation slides for a more comprehensive understanding of AngioDynamics’ strategic imperatives and operational outlook. The company remains steadfast in its pursuit of sustainable growth and operational excellence.

The contents of the Form 8-K filing serve as a testament to AngioDynamics’ dedication to transparency and strategic communication with its valued stakeholders.

The full text of the exhibit 99-1 can be accessed on the Securities and Exchange Commission’s website or through AngioDynamics’ official investor relations channels.

In adherence to regulatory compliance, AngioDynamics underscores that these presentation slides do not constitute a formal filing under the Securities Exchange Act of 1934 or serve as a reference for future filings.

This information was dominated by the AngioDynamics’ regulatory filing disclosed on January 8, 2025, through Form 8-K. It is advisable for investors and interested parties to engage in their thorough due diligence based on this official disclosure from the company.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read AngioDynamics’s 8K filing here.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.